{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:10:57Z","timestamp":1744200657132},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T00:00:00Z","timestamp":1279929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10557-010-6254-8","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T06:39:29Z","timestamp":1279867169000},"page":"319-323","source":"Crossref","is-referenced-by-count":4,"title":["Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia"],"prefix":"10.1007","volume":"24","author":[{"given":"Danny","family":"Dvir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Battler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,24]]},"reference":[{"key":"6254_CR1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/hrt.2005.083659","volume":"93","author":"I Ben-Dor","year":"2007","unstructured":"Ben-Dor I, Battler A. Treatment of stable angina. Heart. 2007;93:868\u201374.","journal-title":"Heart"},{"key":"6254_CR2","doi-asserted-by":"crossref","first-page":"I25","DOI":"10.1002\/clc.20050","volume":"30","author":"BR Chaitman","year":"2007","unstructured":"Chaitman BR, Sano J. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. Clin Cardiol. 2007;30:I25\u201330.","journal-title":"Clin Cardiol"},{"key":"6254_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1007787328732","volume":"12","author":"S Savonitto","year":"1998","unstructured":"Savonitto S, Ardissino D. Selection of drug therapy in stable angina pectoris. Cardiovasc Drugs Ther. 1998;12:197\u2013210.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6254_CR4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00001573-199907000-00011","volume":"14","author":"U Thadani","year":"1999","unstructured":"Thadani U. Treatment of stable angina. Curr Opin Cardiol. 1999;14:349\u201358.","journal-title":"Curr Opin Cardiol"},{"key":"6254_CR5","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/CIRCULATIONAHA.107.187930","volume":"116","author":"TD Fraker Jr","year":"2007","unstructured":"Fraker Jr TD, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC\/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007;116:2762\u201372.","journal-title":"Circulation"},{"key":"6254_CR6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","volume":"27","author":"K Fox","year":"2006","unstructured":"Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341\u201381.","journal-title":"Eur Heart J"},{"key":"6254_CR7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.281.20.1927","volume":"281","author":"PA Heidenreich","year":"1999","unstructured":"Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927\u201336.","journal-title":"JAMA"},{"key":"6254_CR8","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/01.CIR.92.5.1326","volume":"92","author":"CD Furberg","year":"1995","unstructured":"Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326\u201331.","journal-title":"Circulation"},{"key":"6254_CR9","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.281.20.1927","volume":"281","author":"PA Heidenreich","year":"1999","unstructured":"Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927\u201336.","journal-title":"JAMA"},{"key":"6254_CR10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199802193380807","volume":"338","author":"JD Parker","year":"1998","unstructured":"Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520\u201331.","journal-title":"N Engl J Med"},{"key":"6254_CR11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0735-1097(97)00268-4","volume":"30","author":"CJ Pepine","year":"1997","unstructured":"Pepine CJ, Lopez LM, Bell DM, et al. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II). J Am Coll Cardiol. 1997;30:955\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"6254_CR12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00003495-200666050-00010","volume":"66","author":"MA Siddiqui","year":"2006","unstructured":"Siddiqui MA, Keam SJ. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2006;66:693\u2013710.","journal-title":"Drugs"},{"key":"6254_CR13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","volume":"110","author":"C Antzelevitch","year":"2004","unstructured":"Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904\u201310.","journal-title":"Circulation"},{"key":"6254_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","volume":"95","author":"MF Rousseau","year":"2005","unstructured":"Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95:311\u20136.","journal-title":"Am J Cardiol"},{"key":"6254_CR15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, et al. For the Combination Assessment of Ranolazine In Stable Angina (CARISA) investigators: effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA. 2004;291:309\u201316.","journal-title":"JAMA"},{"key":"6254_CR16","doi-asserted-by":"crossref","first-page":"1186e1","DOI":"10.1016\/j.ahj.2006.01.004","volume":"151","author":"DA Morrow","year":"2006","unstructured":"Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN)\u2013TIMI 36 trial. Am Heart J. 2006;151:1186e1\u20139.","journal-title":"Am Heart J"},{"key":"6254_CR17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PH Stone","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"6254_CR18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2337\/dc09-2334","volume":"33","author":"JW Chisholm","year":"2010","unstructured":"Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diab Care. 2010;33:1163\u20138.","journal-title":"Diab Care"},{"key":"6254_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","volume":"27","author":"AD Timmis","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42\u20138.","journal-title":"Eur Heart J"},{"key":"6254_CR20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/0091270004273992","volume":"45","author":"M Jerling","year":"2005","unstructured":"Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45:422\u201333.","journal-title":"J Clin Pharmacol"},{"key":"6254_CR21","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2165\/00003495-200464170-00012","volume":"64","author":"D Simpson","year":"2004","unstructured":"Simpson D, Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs. 2004;64:1941\u201355.","journal-title":"Drugs"},{"key":"6254_CR22","first-page":"34","volume":"8","author":"P Abete","year":"2009","unstructured":"Abete P, Cacciatore F, Testa G, et al. Clinical application of ischemic preconditioning in the elderly. Dose Response. 2009;8:34\u201340.","journal-title":"Dose Response"},{"key":"6254_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0002-9149(97)00279-8","volume":"80","author":"JW Chen","year":"1997","unstructured":"Chen JW, Lee WL, Hsu NW, et al. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol. 1997;80:32\u20138.","journal-title":"Am J Cardiol"},{"key":"6254_CR24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","volume":"359","author":"IONA Study Group","year":"2002","unstructured":"IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet. 2002;359:1269\u201375.","journal-title":"Lancet"},{"key":"6254_CR25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817\u201323.","journal-title":"Circulation"},{"key":"6254_CR26","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529\u201336.","journal-title":"Eur Heart J"},{"key":"6254_CR27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.phrs.2006.03.017","volume":"53","author":"JS Borer","year":"2006","unstructured":"Borer JS. Therapeutic effects of I(f) blockade: evidence and perspective. Pharmacol Res. 2006;53:440\u20135.","journal-title":"Pharmacol Res"},{"key":"6254_CR28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807\u201316.","journal-title":"Lancet"},{"key":"6254_CR29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/14656566.2.5.857","volume":"2","author":"HR Cross","year":"2001","unstructured":"Cross HR. Trimetazidine for stable angina pectoris. Expert Opin Pharmacother. 2001;2:857\u201375.","journal-title":"Expert Opin Pharmacother"},{"key":"6254_CR30","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","volume":"22","author":"H Szwed","year":"2001","unstructured":"Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using Trimetazidine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22:2267\u201374.","journal-title":"Eur Heart J"},{"key":"6254_CR31","first-page":"CD003614","volume":"19","author":"A Ciapponi","year":"2005","unstructured":"Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005;19:CD003614.","journal-title":"Cochrane Database Syst Rev"},{"key":"6254_CR32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/j.1875-9114.1987.tb03503.x","volume":"7","author":"RE Nitz","year":"1987","unstructured":"Nitz RE, Fiedler VB. Molsidomine: alternative approaches to treat myocardial ischemia. Pharmacotherapy. 1987;7:28\u201337.","journal-title":"Pharmacotherapy"},{"key":"6254_CR33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2004.12.018","volume":"180","author":"C Hove Van","year":"2005","unstructured":"Van Hove C, Carreer-Bruhwyler F, G\u00e9czy J, et al. Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina. Atherosclerosis. 2005;180:399\u2013405.","journal-title":"Atherosclerosis"},{"key":"6254_CR34","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/eurheartj\/12.9.994","volume":"12","author":"F Wagner","year":"1991","unstructured":"Wagner F, Gohlke-B\u00e4rwolf C, Trenk D, et al. Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Eur Heart J. 1991;12:994\u20139.","journal-title":"Eur Heart J"},{"key":"6254_CR35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2004.01.007","volume":"98","author":"R Messin","year":"2005","unstructured":"Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris. Int J Cardiol. 2005;98:79\u201389.","journal-title":"Int J Cardiol"},{"key":"6254_CR36","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/hc1002.105938","volume":"105","author":"A Masumoto","year":"2002","unstructured":"Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105:1545\u20137.","journal-title":"Circulation"},{"key":"6254_CR37","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jacc.2005.07.047","volume":"46","author":"RM Vicari","year":"2005","unstructured":"Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803\u201311.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-010-6254-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-010-6254-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-010-6254-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:28:08Z","timestamp":1559237288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-010-6254-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,24]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["6254"],"URL":"https:\/\/doi.org\/10.1007\/s10557-010-6254-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,24]]}}}